Technology Access Program Scientist

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acrotech Biopharma

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altavant Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Anagenex

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Aruvant

Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.

<p>Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.</p>


Find a biotech startup job.